UniSA researchers are putting cancer patients at the heart of clinical trials

From bench to bedside, the journey towards new cancer therapies is full of challenges. Clinical trials – where new treatments are tested on people – are vital, but with fewer than five per cent of cancer patients participating worldwide, it’s a long road to travel.

Image Credit: University of South Australia

Now, researchers from the University of South Australia are putting cancer patients front and center of a new study to find out what works well (and what needs improvement) in clinical trials in Australia.

Funded by Cancer Council’s Beat Cancer Project the study is part of broader research to improve access to clinical trials and systems across Adelaide.

Just beyond Daffodil Day 2021, this is a timely reminder about the importance of research to change the lives of people affected by cancer.

UniSA Senior Research Fellow and Research and Strategy Manager at the Rosemary Bryant AO Research Centre, Greg Sharplin, says understanding the experiences of people who participate in clinical trials is essential to inform best practice.

Every day, nearly 400 new cases of cancer are diagnosed in Australia. While our survival rates are among the best in the world, clinical trials are fundamental to developing new and more effective cancer treatments.

While there are many barriers to trial participation, few have been researched from a patient perspective, which leave us in the dark when it comes to creating better experiences – our study aims to change this.”

Greg Sharplin, UniSA Senior Research Fellow and Research and Strategy Manager, Rosemary Bryant AO Research Centre

Lead investigator and medical oncologist, Professor Ian Olver AO, is acutely aware of the importance of identifying barriers to participating in clinical trials.

“Working with people who have participated in cancer trials we know that an awareness of the trials themselves is a massive issue. If clinicians and patients aren’t aware of the range of clinical trials on offer, it’s impossible for them to take part,” Professor Olver says.

“By talking with clinical trial participants, we’re hoping to learn more about how they were informed and supported, both before, during and after their treatment.

“And, by capturing people’s experiences of clinical trials, we can identify what could be done better to prepare or support individuals with cancer to participate in clinical trials in South Australia.”

Providing high-quality care to clinical trial participants is the central driver behind the research.

A unique benefit of clinical trials is that they can provide access to the latest medical research, enabling cancer patients to receive novel and alternative therapy options, not yet available on the market.

Karen van Gorp was diagnosed with Stage IV melanoma, she participated in an immunotherapy trial (2013-2015) for a new cancer drug now on the market. Today, she cancer free, and an advocate for clinical trials.

“Understanding that clinical trials are safe is essential for potential participants, but for patients and specialists, knowing about what trials are available is a big hurdle,” van Gorp says.

“For me, the clinical trial was a game changer. I’d been told there were no treatments available to me, so when I discovered the trial, I saw it as a last resort.

“Since I finished treatment, I’ve been cancer free.

“The new therapies I was exposed to via the clinical trial saved my life.”


University of South Australia

Posted in: Drug Trial News | Medical Condition News

Tags: Cancer, Clinical Trial, Heart, Immunotherapy, Medical Research, Melanoma, Research

Comments (0)

Source: Read Full Article